Reference scaled BE - FDA (and FARTSSIE update) [RSABE / ABEL]

posted by KR – India, 2010-04-27 15:14 (5893 d 10:01 ago) – Posting: # 5246
Views: 41,807

Dear Dave,

It is really a valuable and appreciable work done. Thanks.

However, in "Bioequivalence, Replicate" sheet, I have one concern: FDA recommends 3 period, 3 sequence crossover study but there is only one option of 3 period, 2 sequence (ABB/BAA) in the excel sheet which is not matching with the sequences given in the FDA recommendation. So in this case,the sample size calculated from the xls sheet and the sample size required for FDA recommended reference scaled study will remain the same ? Same case is for 4 period replicate study also.

Kindly provide your valuable comment on the same.

Thanks once again.

KR


Edit: Full quote removed (like in almost all your replies). Please delete anything from the text of the original poster which is not necessary in understanding your answer; see also this post! [Jaime]

Complete thread:

UA Flag
Activity
 Admin contact
23,654 posts in 4,992 threads, 1,571 registered users;
136 visitors (0 registered, 136 guests [including 20 identified bots]).
Forum time: 01:16 CEST (Europe/Vienna)

The idea is to try and give all the information to help others
to judge the value of your contribution;
not just the information that leads to judgment
in one particular direction or another.    Richard Feynman

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5